Published in J Neural Transm (Vienna) on January 01, 1997
The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. CMAJ (2001) 2.15
A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities. Psychopharmacology (Berl) (2003) 1.01
The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): an evidence-based review. Psychopharmacology (Berl) (2007) 1.00
A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') on dopamine neurones in mouse brain. Br J Pharmacol (2001) 0.98
Dance clubbing on MDMA and during abstinence from Ecstasy/MDMA: prospective neuroendocrine and psychobiological changes. Neuropsychobiology (2008) 0.98
White-matter abnormalities in brain during early abstinence from methamphetamine abuse. Psychopharmacology (Berl) (2010) 0.98
Cannabis and Ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users. J Neural Transm (Vienna) (2007) 0.95
Saturday night fever in ecstasy/MDMA dance clubbers: Heightened body temperature and associated psychobiological changes. Temperature (Austin) (2014) 0.92
Cortisol and 3,4-methylenedioxymethamphetamine: neurohormonal aspects of bioenergetic stress in ecstasy users. Neuropsychobiology (2009) 0.90
Role of serotonin and/or norepinephrine in the MDMA-induced increase in extracellular glucose and glycogenolysis in the rat brain. Eur J Pharmacol (2010) 0.83
The serotonin syndrome. Am J Psychiatry (1991) 7.11
Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy") Lancet (1992) 7.01
Large-scale neurocognitive networks and distributed processing for attention, language, and memory. Ann Neurol (1990) 5.60
Structure and function of the brain serotonin system. Physiol Rev (1992) 5.30
'Eve' and 'Ecstasy'. A report of five deaths associated with the use of MDEA and MDMA. JAMA (1987) 4.49
The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci (1990) 4.34
Dexfenfluramine neurotoxicity in brains of non-human primates. Lancet (1991) 3.94
Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J Neurochem (1971) 3.34
Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage. Trends Neurosci (1988) 3.13
Ecstasy and neurodegeneration. BMJ (1996) 2.93
A comparison of three methods of glycogen measurement in tissues. Anal Biochem (1974) 2.83
Multiple severe complications from recreational ingestion of MDMA ('Ecstasy') JAMA (1987) 2.70
Ecstasy, 3-4 methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia. J R Soc Med (1991) 2.42
Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine ('Ecstasy') Br J Psychiatry (1994) 2.35
Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol (1993) 2.25
Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs (1987) 2.20
Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). Psychopharmacology (Berl) (1995) 2.07
Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science (1985) 1.88
Neuroendocrine and mood responses to intravenous L-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users. Preliminary observations. Arch Gen Psychiatry (1989) 1.86
Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat. Pharmacol Biochem Behav (1991) 1.76
Demonstration in vivo of reduced serotonin responsivity in the brain of untreated depressed patients. Am J Psychiatry (1996) 1.72
Acute renal failure after ecstasy. BMJ (1992) 1.70
The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci U S A (1992) 1.68
Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs (1987) 1.68
Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharmacol Exp Ther (1994) 1.63
Incidence of recreational use of 3,4-methylenedimethoxymethamphetamine (MDMA, "ecstasy") on an undergraduate campus. N Engl J Med (1987) 1.57
Hyperpyrexia and rhabdomyolysis after MDMA ("ecstasy") abuse. Lancet (1992) 1.56
Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci (1988) 1.52
Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J Pharmacol Exp Ther (1980) 1.49
Dual serotoninergic projections to forebrain in the rat: morphologically distinct 5-HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivatives. J Comp Neurol (1991) 1.47
Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res (1988) 1.44
Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology (1988) 1.41
(+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA (1988) 1.41
Ontogeny of the serotonergic system in the rat: serotonin as a developmental signal. Ann N Y Acad Sci (1990) 1.38
The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol (1995) 1.35
3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther (1987) 1.33
Acute and subchronic effects of methylenedioxymethamphetamine [(+/-)MDMA] on locomotion and serotonin syndrome behavior in the rat. Pharmacol Biochem Behav (1989) 1.29
Role of dopamine in the neurotoxic effects of methamphetamine. J Pharmacol Exp Ther (1985) 1.29
Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol (1988) 1.29
Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther (1987) 1.28
Modulatory role of serotonin in neural information processing: implications for human psychopathology. Psychol Bull (1992) 1.28
Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther (1994) 1.27
Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem Pharmacol (1996) 1.18
Glial glycogen stores affect neuronal survival during glucose deprivation in vitro. J Cereb Blood Flow Metab (1993) 1.18
Methylenedioxymethamphetamine-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors. Brain Res (1990) 1.16
The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol (1986) 1.14
Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J Neurochem (1996) 1.14
Hyperthermia following MDMA administration in rats: effects of ambient temperature, water consumption, and chronic dosing. Physiol Behav (1995) 1.14
Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacology (Berl) (1989) 1.14
Effect of ambient temperature on hyperthermia and hyperkinesis induced by 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") in rats. Psychopharmacology (Berl) (1994) 1.14
The spin trap reagent alpha-phenyl-N-tert-butyl nitrone prevents 'ecstasy'-induced neurodegeneration of 5-hydroxytryptamine neurones. Eur J Pharmacol (1995) 1.13
PET studies of presynaptic monoamine metabolism in depressed patients and healthy volunteers. Pharmacopsychiatry (1994) 1.13
Stimulation of astroglial 5-HT1A receptors releases the serotonergic growth factor, protein S-100, and alters astroglial morphology. Brain Res (1990) 1.12
Neurotoxicity of MDMA and related compounds: anatomic studies. Ann N Y Acad Sci (1990) 1.12
Activity of brain serotonergic neurons in the behaving animal. Pharmacol Rev (1991) 1.12
Subarachnoid haemorrhage associated with MDMA abuse. J Neurol Neurosurg Psychiatry (1993) 1.11
5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine. Br J Pharmacol (1993) 1.11
'Ecstasy' and intracerebral haemorrhage. Scott Med J (1992) 1.08
Gangliosides normalize distorted single-cell intracellular free Ca2+ dynamics after toxic doses of glutamate in cerebellar granule cells. Proc Natl Acad Sci U S A (1990) 1.03
Methamphetamine-induced neuronal damage: a possible role for free radicals. Neuropharmacology (1989) 1.02
Lasting neuropsychiatric sequelae of (+-)methylenedioxymethamphetamine ('ecstasy') in recreational users. J Clin Psychopharmacol (1991) 1.01
Multiple methamphetamine injections induce marked increases in extracellular striatal dopamine which correlate with subsequent neurotoxicity. Brain Res (1991) 1.01
Age modulates the long-term but not the acute effects of the serotonergic neurotoxicant 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther (1994) 1.00
Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates. J Neurochem (1981) 0.99
[3H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues. Eur J Pharmacol (1991) 0.98
Accidental ingestion of 'Ecstasy' (3,4-methylenedioxymethylamphetamine). Arch Dis Child (1992) 0.97
The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur J Pharmacol (1992) 0.97
Development and lesion induced reorganization of the cortical representation of the rat's body surface as revealed by immunocytochemistry for serotonin. J Comp Neurol (1990) 0.96
Effects of certain hallucinogenic amphetamine analogues on the release of [3H]serotonin from rat brain synaptosomes. J Med Chem (1982) 0.94
Ecstasy, the serotonin syndrome, and neuroleptic malignant syndrome--a possible link? JAMA (1993) 0.94
Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine. Neuroscience (1989) 0.94
Awakening the sleeping giant: anatomy and plasticity of the brain serotonergic system. J Clin Psychiatry (1991) 0.93
Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists. Eur J Pharmacol (1994) 0.93
The neurotoxic effects of methamphetamine on 5-hydroxytryptamine and dopamine in brain: evidence for the protective effect of chlormethiazole. Neuropharmacology (1992) 0.92
Subjective reports on the effects of the MDMA ('ecstasy') experience in humans. Prog Neuropsychopharmacol Biol Psychiatry (1995) 0.92
Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther (1988) 0.91
Experimental studies on the role of serotonin in cognition. Prog Neurobiol (1995) 0.91
Microdialysis studies on 3,4-methylenedioxymethamphetamine-induced dopamine release: effect of dopamine uptake inhibitors. J Pharmacol Exp Ther (1991) 0.91
Lack of serotonin neurotoxicity after intraraphe microinjection of (+)-3,4-methylenedioxymethamphetamine (MDMA). Brain Res Bull (1992) 0.91
Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. Life Sci (1990) 0.91
5HT-2 mediation of acute behavioral effects of hallucinogens in rats. Psychopharmacology (Berl) (1990) 0.91
The functional significance of the pentose phosphate pathway in synaptosomes: protection against peroxidative damage by catecholamines and oxidants. J Neurochem (1982) 0.90
Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Ann N Y Acad Sci (1992) 0.90
MDMA: historical perspectives. Ann N Y Acad Sci (1990) 0.90
3,4-Methylenedioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys. J Pharmacol Exp Ther (1989) 0.90
Ultrastructural relationships of serotonin axon terminals in the cerebral cortex of the adult rat. J Comp Neurol (1989) 0.89
Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate. Neurotoxicology (1989) 0.89
Immunocytochemical evidence for methamphetamine-induced serotonergic axon loss in the rat brain. Synapse (1991) 0.89
Characterization of [3H]paroxetine binding to rat cortical membranes. Eur J Pharmacol (1985) 0.88
Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ('Ecstasy') to rats. Neuropharmacology (1994) 0.87
Methamphetamine-induced serotonin neurotoxicity is mediated by superoxide radicals. Brain Res (1995) 0.87
The background and chemistry of MDMA. J Psychoactive Drugs (1987) 0.87
Effects of 3,4-dihydroxymethamphetamine and 2,4,5-trihydroxymethamphetamine, two metabolites of 3,4-methylenedioxymethamphetamine, on central serotonergic and dopaminergic systems. J Pharmacol Exp Ther (1992) 0.86
Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals. Toxicol Appl Pharmacol (1973) 0.86
Synaptic loss following removal of serotoninergic fibers in newly hatched and adult chickens. J Neurobiol (1993) 0.86
Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity. Pharmacol Biochem Behav (1993) 0.85
Effects of p-chloroamphetamine on brain serotonin neurons. Neurochem Res (1992) 0.85
Imaging of serotonin and dopamine transporters in the living human brain. Eur J Nucl Med (1995) 0.84
Persistent effects of (+/- )3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on human sleep. Sleep (1993) 0.84
The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J Pharmacol Exp Ther (1995) 0.84
Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood (1996) 5.31
Association of genetic variation in FTO with risk of obesity and type 2 diabetes with data from 96,551 East and South Asians. Diabetologia (2011) 2.37
Epidemiological link between exposure to poultry and all influenza A(H7N9) confirmed cases in Huzhou city, China, March to May 2013. Euro Surveill (2013) 2.34
Homing receptors and vascular addressins: cell adhesion molecules that direct lymphocyte traffic. Immunol Rev (1989) 2.06
Migration of dendritic cells in response to formyl peptides, C5a, and a distinct set of chemokines. J Immunol (1995) 2.06
Monitoring the brain: processed electroencephalogram and peri-operative outcomes. Anaesthesia (2014) 2.02
Receptor expression and responsiveness of human dendritic cells to a defined set of CC and CXC chemokines. J Immunol (1997) 2.02
Induction of natural killer cell migration by monocyte chemotactic protein-1, -2 and -3. Eur J Immunol (1994) 2.01
Striking a balance: modulation of the actin cytoskeleton by Salmonella. Proc Natl Acad Sci U S A (2000) 1.89
Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. Am J Psychiatry (1998) 1.86
Statistical analysis of MPSS measurements: application to the study of LPS-activated macrophage gene expression. Proc Natl Acad Sci U S A (2005) 1.84
Causes of death among people with convulsive epilepsy in rural West China: a prospective study. Neurology (2011) 1.77
Repeated embolism and multiple aneurysms: central nervous system manifestations of cardiac myxoma. Eur J Neurol (2008) 1.72
Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry (2004) 1.63
T cell receptor V beta repertoire in an acute infection of rhesus monkeys with simian immunodeficiency viruses and a chimeric simian-human immunodeficiency virus. J Exp Med (1995) 1.61
Clinical features of convulsive status epilepticus: a study of 220 cases in western China. Eur J Neurol (2009) 1.53
Mst1/2 signalling to Yap: gatekeeper for liver size and tumour development. Br J Cancer (2010) 1.53
The pathogenesis of gonococcal urethritis in men: confocal and immunoelectron microscopic analysis of urethral exudates from men infected with Neisseria gonorrhoeae. J Infect Dis (1996) 1.52
In vivo crypt surface hyperproliferation is decreased by butyrate and increased by deoxycholate in normal rat colon: associated in vivo effects on c-Fos and c-Jun expression. JPEN J Parenter Enteral Nutr (1997) 1.50
Normalization of diabetes in spontaneously diabetic cynomologus monkeys by xenografts of microencapsulated porcine islets without immunosuppression. J Clin Invest (1996) 1.50
Moderate alcohol consumption in social drinkers raises plasma homocysteine levels: a contradiction to the 'French Paradox'? Alcohol Alcohol (2001) 1.50
The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. A placebo-controlled, double-blind, randomized, cross-over study followed by an open treatment over 3 weeks. Psychopharmacology (Berl) (2003) 1.45
Eosinophilia-myalgia syndrome in Germany: an epidemiologic review. Mayo Clin Proc (1994) 1.44
Changes in heart rate during obstructive sleep apnoea. Eur Respir J (1992) 1.43
Nervous system defects of AnkyrinB (-/-) mice suggest functional overlap between the cell adhesion molecule L1 and 440-kD AnkyrinB in premyelinated axons. J Cell Biol (1998) 1.43
Receptors and transduction pathways for monocyte chemotactic protein-2 and monocyte chemotactic protein-3. Similarities and differences with MCP-1. J Immunol (1994) 1.42
Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J Neurochem (2002) 1.40
[Recommendations for diagnosis, therapy and long-term management of patients with sleep apnea]. Med Klin (Munich) (1991) 1.40
A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res (1994) 1.39
Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry (2006) 1.38
Improved electrophoretic separation and immunoblotting of beta-amyloid (A beta) peptides 1-40, 1-42, and 1-43. Electrophoresis (1997) 1.37
Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS (1997) 1.32
Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry (2004) 1.31
Lack of the p50 subunit of nuclear factor-kappaB increases the vulnerability of hippocampal neurons to excitotoxic injury. J Neurosci (1999) 1.30
Adenosine A3 receptor expression and function in eosinophils. Am J Respir Cell Mol Biol (1997) 1.28
Immunohistochemical localization of the D1 dopamine receptor in rat brain reveals its axonal transport, pre- and postsynaptic localization, and prevalence in the basal ganglia, limbic system, and thalamic reticular nucleus. Proc Natl Acad Sci U S A (1992) 1.27
Age-associated changes in the densities of presynaptic monoamine transporters in different regions of the rat brain from early juvenile life to late adulthood. Brain Res Dev Brain Res (2000) 1.26
Effect of exogenous sialylation of the lipooligosaccharide of Neisseria gonorrhoeae on opsonophagocytosis. Infect Immun (1992) 1.24
Pivotal role for acidic sphingomyelinase in cerebral ischemia-induced ceramide and cytokine production, and neuronal apoptosis. J Mol Neurosci (2000) 1.22
Role of stress-activated mitogen-activated protein kinase (p38) in beta 2-integrin-dependent neutrophil adhesion and the adhesion-dependent oxidative burst. J Immunol (1998) 1.21
Immune biology of macaque lymphocyte populations during mycobacterial infection. Clin Exp Immunol (2003) 1.20
Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry (2001) 1.19
Apparent genetic redundancy facilitates ecological plasticity for nitrate transport. EMBO J (2001) 1.18
Erythropoietin: a candidate compound for neuroprotection in schizophrenia. Mol Psychiatry (2004) 1.18
Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group. J Clin Psychiatry (1999) 1.17
Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing. Exp Neurol (2009) 1.17
Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry (2004) 1.16
Expression of adhesion molecules, platelet-activating factor, and chemokines by Kaposi's sarcoma cells. J Immunol (1994) 1.15
Sleep apnea syndrome and cerebral hemodynamics. Chest (1996) 1.15
Modulation of aromatase expression in the breast tissue by ERR alpha-1 orphan receptor. Cancer Res (1998) 1.15
Haloperidol concentrations elevated in Chinese patients. Psychiatry Res (1984) 1.14
Elliptic flow of charged particles in Pb-Pb collisions at sqrt[S(NN)] = 2.76 TeV. Phys Rev Lett (2010) 1.12
Biosynthesis of the linkage region of glycosaminoglycans: cloning and activity of galactosyltransferase II, the sixth member of the beta 1,3-galactosyltransferase family (beta 3GalT6). J Biol Chem (2001) 1.12
A new monoclonal antibody (5D3-F7) which recognizes human monocyte-chemotactic protein-1 but not related chemokines. Development of a sandwich ELISA and in situ detection of producing cells. J Immunol Methods (1994) 1.12
Particle-yield modification in jetlike azimuthal dihadron correlations in Pb-Pb collisions at √s(NN)=2.76 TeV. Phys Rev Lett (2012) 1.11
Aromatase gene expression and its exon I usage in human breast tumors. Detection of aromatase messenger RNA by reverse transcription-polymerase chain reaction. J Steroid Biochem Mol Biol (1996) 1.11
Tn916-generated, lipooligosaccharide mutants of Neisseria meningitidis and Neisseria gonorrhoeae. Infect Immun (1994) 1.10
Microheterogeneity of Neisseria lipooligosaccharide: analysis of a UDP-glucose 4-epimerase mutant of Neisseria meningitidis NMB. Infect Immun (1995) 1.09
Autocrine and paracrine actions of breast tumor aromatase. A three-dimensional cell culture study involving aromatase transfected MCF-7 and T-47D cells. J Steroid Biochem Mol Biol (1998) 1.09
Assessment of intracranial hemodynamics in sleep apnea syndrome. Stroke (1992) 1.08
Multiple matching scheme for broadband 0.72Pb(Mg(13)Nb(23))O(3)-0.28PbTiO(3) single crystal phased-array transducer. J Appl Phys (2009) 1.08
Transverse momentum distribution and nuclear modification factor of charged particles in p+Pb collisions at sqrt[s(NN)] = 5.02 TeV. Phys Rev Lett (2013) 1.08
Targeted deletion of the lipopolysaccharide (LPS)-binding protein gene leads to profound suppression of LPS responses ex vivo, whereas in vivo responses remain intact. J Exp Med (1997) 1.06
Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages. J Immunol (1995) 1.06
Higher harmonic anisotropic flow measurements of charged particles in Pb-Pb collisions at sqrt(s(NN)) = 2.76 TeV. Phys Rev Lett (2011) 1.05
Early methylphenidate administration to young rats causes a persistent reduction in the density of striatal dopamine transporters. J Child Adolesc Psychopharmacol (2001) 1.05
Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias. Mol Psychiatry (2007) 1.05
Adverse drug reactions. An epidemiological study at psychiatric hospitals. Acta Psychiatr Scand (1984) 1.05
Beta-subunit-dependent modulation of hSlo BK current by arachidonic acid. J Neurophysiol (2006) 1.04
Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment. J Nutr Health Aging (2009) 1.04
Protein farnesyltransferase in plants: molecular characterization and involvement in cell cycle control. Plant Cell (1996) 1.04
Expiratory neural activities in gasping. J Appl Physiol (1985) (1989) 1.04
Binding characteristics of seven inhibitors of human aromatase: a site-directed mutagenesis study. Cancer Res (1996) 1.03
Leukemia inhibitory factor (LIF) and LIF receptor in human lung. Distribution and regulation of LIF release. Am J Respir Cell Mol Biol (1999) 1.02
Differing control of neural activities during various portions of expiration in the cat. J Physiol (1989) 1.02
Different signaling pathways for CD18-mediated adhesion and Fc-mediated phagocytosis. Response of neutrophils to LPS. J Immunol (1994) 1.01
Substance P (NK1)- and neurokinin A (NK2)-receptor gene expression in inflammatory airway diseases. Am J Physiol (1995) 1.01
High-frequency repetitive transcranial magnetic stimulation delays rapid eye movement sleep. Neuroreport (1998) 1.00
XRCC1 Arg399Gln and Arg194Trp polymorphisms in prostate cancer risk: a meta-analysis. Prostate Cancer Prostatic Dis (2011) 1.00
Cloning of a mouse beta 1,3 N-acetylglucosaminyltransferase GlcNAc(beta 1,3)Gal(beta 1,4)Glc-ceramide synthase gene encoding the key regulator of lacto-series glycolipid biosynthesis. J Biol Chem (2001) 0.99
Acupuncture for Bell's palsy. Cochrane Database Syst Rev (2007) 0.99
Designing small-molecule switches for protein-protein interactions. Science (2000) 0.99
The AMSP drug safety program: methods and global results. Pharmacopsychiatry (2004) 0.98
Incidence, management and mortality of acute hypoxemic respiratory failure and acute respiratory distress syndrome from a prospective study of Chinese paediatric intensive care network. Acta Paediatr (2010) 0.98
Production of muons from heavy flavor decays at forward rapidity in pp and Pb-Pb collisions at sqrt[s(NN)]=2.76 TeV. Phys Rev Lett (2012) 0.98
Interleukin-12 is chemotactic for natural killer cells and stimulates their interaction with vascular endothelium. Blood (1994) 0.98
Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study. Pharmacopsychiatry (2002) 0.98
"Helicobacter heilmannii" infection in a patient with gastric cancer. Dig Dis Sci (1995) 0.97
Cytoskeletal disruption accelerates caspase-3 activation and alters the intracellular membrane reorganization in DNA damage-induced apoptosis. Exp Cell Res (2000) 0.97
Acquisition of intact allogeneic human leukocyte antigen molecules by human dendritic cells. Blood (2000) 0.97
Molecular basis for the constitutive activity of estrogen-related receptor alpha-1. J Biol Chem (2001) 0.97
Isoform pattern of 14-3-3 proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurochem (1999) 0.97
Direct sequencing analysis of exon 1 of the c-K-ras gene shows a low frequency of mutations in human pancreatic adenocarcinomas. Oncogene (1989) 0.97
Nonopsonic phagocytosis of group C Neisseria meningitidis by human neutrophils. Infect Immun (1998) 0.96
The relationship of fluorosis and brick tea drinking in Chinese Tibetans. Environ Health Perspect (1996) 0.96
Neuroprotective role for the p50 subunit of NF-kappaB in an experimental model of Huntington's disease. J Mol Neurosci (2000) 0.96
A high-resolution chemical and structural study of framboidal pyrite formed within a low-temperature bacterial biofilm. Geobiology (2008) 0.96